



Digital healthcare for respiratory disease

Tony Keating
CEO and Managing Director
tony@resapp.health

Annual General Meeting
28 November 2019

Disclaimer

This presentation has been prepared by ResApp Health Limited (“ResApp”). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp’s strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of ResApp. The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with ResApp’s other periodic and continuous disclosure announcements, which are available at <https://www.resapphealth.com.au/investor-relations/asx-announcements/>.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

About ResApp Health

that has developed

We are a leading digital health company ~~developing~~ the world's first clinically-validated, regulatory-approved respiratory disease point-of-care diagnostic test and management tools for smartphones.

Highlights of the past year

Clinical



- ✓ Completed US-based SMARTCOUGH-C-2 study
- ✓ Positive results from pivotal adult clinical study (Breathe Easy)
- ✓ Positive results from pivotal at-home sleep apnoea study
- ✓ Published pivotal paediatric clinical study (Breathe Easy) in *Respiratory Research*

Regulatory




- ✓ Submitted De Novo application to US FDA
- ✓ CE Mark received for both paediatric and adult use
- ✓ TGA approval for paediatric use (adult use submitted)

Commercial



- ✓ Announced development of wearable and handheld devices
- ✓ Formed Industry Advisory Board with globally-recognised healthcare leaders
- ✓ Selected to join Startup Creosphere program by Sanofi
- ✓ Partnership with Coviu to deploy ResAppDx-EU on Coviu's telehealth platform
- ✓ Expansion of business development, sales and marketing team

Continuing to build a strong product portfolio



Significant milestones over the next 6 months

- ResAppDx-EU adult use Australian TGA decision
- ResAppDx-US paediatric use US FDA decision
- Sleep apnoea at-home screening product CE Mark submission
- Prototype wearable and handheld devices
- German hospital pilot project
- Startup Creasphere program with Sanofi
- CoviU integration
- Update on US DARPA Warfighter program with Lockheed Martin
- Commercialisation activities in Europe, Australia and the US

How we create long-term value

We are focused on delivering the **best audio-based algorithms for measuring lung health**, creating the **easiest to use software**, and working with **world-class partners** to make a real impact on how patients and their doctors diagnose, manage and treat respiratory disease.